AgeneBio Received US Patent

Agenebio Inc. was issued U.S. Patent No. 8,604,075, “Methods and compositions for improving cognitive function,” and No. 8,510,055, “Methods for characterizing and treating cognitive impairment in aging and disease.” Both cover the company’s programs for Alzheimer’s disease and other cognitive disorders.